Standard BP control

Phase 3Small molecule

NNational Heart, Lung, and Blood Institute (NHLBI)

Standard BP control is one of 71 small molecule programs targeting Primary Aldosteronism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary AldosteronismNot yet recruiting

Atrial FibrillationActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Primary AldosteronismPreclinical

Not yet recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Diabetic RetinopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Standard BP control

NNational Heart, Lung, and Blood Institute (NHLBI)

Phase 3

1 2

Calquence

AstraZeneca

Preclinical

1 3

Calan

VVal Adams

Preclinical

4 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 7

Statin

Bristol-Myers Squibb

Preclinical

1 8

Warfarin Sodium

Boehringer Ingelheim

Preclinical

3 9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

BTK Inhibitor

Ascentage Pharma Group Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2036

PreclinicalNot yet recruiting

Primary Aldosteronism

NCT07673445

Clinical

Trials by Indication[1]

Blood Pressure2 trials

Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients

Unknown status·—·N/A·NCT03015311·8,000 enrolled

Feasibility Study of the Intensive Systolic Blood Pressure Control

Unknown status·SSecond Affiliated Hospital of Nanchang University·Phase 4·NCT02817503·100 enrolled

Atrial Fibrillation1 trial

Cardiovascular Risk Reduction in Atrial Fibrillation Trial

Unknown status·—·N/A·NCT04347330·1,675 enrolled

Diabetic Retinopathy1 trial

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00542178·3,472 enrolled

Primary Aldosteronism1 trial

Intensive Versus Standard Blood Pressure Control in Patients With Primary Aldosteronism (Intensia-Aldo): A Multi-center, Randomized Controlled Trial

Not yet recruiting·CChongqing Medical University·Preclinical·NCT07673445·3,830 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Standard BP control. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard BP control compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard BP control. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

Standard BP control

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2036

Trials by Indication[1]

Blood Pressure2 trials

Atrial Fibrillation1 trial

Diabetic Retinopathy1 trial

Primary Aldosteronism1 trial

References

Drug Info

Quick Facts

Related News